Rubius_Logo.jpg
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
September 01, 2021 09:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
August 30, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 09, 2021 08:00 ET | Rubius Therapeutics
First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Patients with Advanced Solid Tumors New Cohorts Added in Phase...
Rubius_Logo.jpg
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
July 29, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
July 22, 2021 08:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
July 15, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
June 23, 2021 16:01 ET | Rubius Therapeutics
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 20, 2021 08:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
May 19, 2021 17:02 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
May 12, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...